Enhancement of cannabidiol oral bioavailability through the development of nanostructured lipid carriers: In vitro and in vivo evaluation studies
Drug Delivery and Translational Research · 2025-08 · 15 (8) · 2722-2732
DOI: 10.1007/s13346-024-01766-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Delivery and Translational Research, online erschienen am 30.12.2024. Verfasst von Iman E Taha und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS, 38677, USA. Hauptthemen laut MEDLINE: Cannabidiol, Drug Carriers, Nanostructures, Lipids. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cannabidiol (CBD) is a natural product isolated from the Cannabis sativa plant that was approved by the United States Food and Drug Administration (US FDA) for the treatment of resistant epilepsy. Despite its therapeutic potential, CBD’s clinical application is limited by its poor aqueous solubility and low oral bioavailability. The primary aim of this research was to enhance the aqueous solubility and oral bioavailability of CBD by developing nanostructured lipid carriers (NLCs) using conventional hot homogenization method (CHH). In the current study, nine CBD NLC formulations were developed through CHH, of which, NLC5 emerged as the most promising formulation, exhibiting high CBD entrapment efficiency (99.23%), particle size of 207 nm, a polydispersity index of 0.19, and a zeta potential of -26 mV. Additionally, drug release testing for NLC5 showed a high CBD release rate of more than 90% within 15 min, indicating an enhancement of CBD dissolving rate compared to pure CBD. The in vivo pharmacokinetic study of NLC5 formulation showed 27% CBD oral bioavailability. Furthermore, Stability studies conducted at 4 °C and 25 °C on this formulation over three months, revealed consistent parameters, underscoring the robustness of the formulation. In conclusion, the successful formulation of CBD-loaded NLCs resulted in improved CBD release rate, enhanced oral bioavailability of CBD, and maintained stability, making it a promising approach for the effective delivery of CBD. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS, 38677, USA.
- National Center for Natural Product Research, University of Mississippi, University, MS, 38677, USA.
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS, 38677, USA. eashour@olemiss.edu.
ORCID-Profile: Eman A Ashour
Zitieren
APA
Taha, I. E., ElSohly, M. A., Radwan, M. M., Elkanayati, R. M., Wanas, A., Joshi, P. H., & Ashour, E. A. (2025). Enhancement of cannabidiol oral bioavailability through the development of nanostructured lipid carriers: In vitro and in vivo evaluation studies. Drug Delivery and Translational Research, 15(8), 2722-2732. https://doi.org/10.1007/s13346-024-01766-9
Vancouver
Taha IE, ElSohly MA, Radwan MM, Elkanayati RM, Wanas A, Joshi PH, et al. Enhancement of cannabidiol oral bioavailability through the development of nanostructured lipid carriers: In vitro and in vivo evaluation studies. Drug Delivery and Translational Research. 2025;15(8):2722-2732. doi:10.1007/s13346-024-01766-9
BibTeX
@article{Taha2025,
author = {Taha, Iman E and ElSohly, Mahmoud A and Radwan, Mohamed M and Elkanayati, Rasha M and Wanas, Amira and Joshi, Poorva H and Ashour, Eman A},
title = {Enhancement of cannabidiol oral bioavailability through the development of nanostructured lipid carriers: In vitro and in vivo evaluation studies},
journal = {Drug Delivery and Translational Research},
year = {2025},
volume = {15},
number = {8},
pages = {2722--2732},
doi = {10.1007/s13346-024-01766-9}
}
EUVIMED